



Know Your DLCO

- Diffusion capacity (DLCO) is the most powerful predictor of survival in COPD patients.
- Risk of hospitalization increases 3x when DLCO and FEV1 are below 50% of predicted.




Why DLCO?


Differential diagnosis between asthma and emphysema



To show a comorbidity of COPD in heart failure patients



DLCO is used as an indicator of lung disease severity



To detect interstitial lung disease early, before lung volumes become decreased



Simple. Certain. Proven.

EasyOne Pro – Portable Pulmonary Function Testing




EasyOne Pro® provides the **most efficient** and **accurate** way to test lung function in any setting. Engineered using our patented TrueFlow™ and TrueCheck™ technology, the EasyOne Pro® eliminates all sources of error, saves time and gives your patients the best pulmonary care in your practice or lung function lab.

DLCO testing adds only **5 minutes** to spirometry and doubles reimbursement

Instant interpretation of results with the **ATS/ERS decision tree**

Bringing the diagnosis **closer to the patient** with point of care testing

Proven worldwide:
NIH, COPDGene, GOLD, NASA, World Trade Center



All clinical statements come from these sources:

ERS Journal, Lung function indices for predicting mortality in chronic obstructive pulmonary disease, January 2013
COPDGene, DLCO Influences Morbidity Beyond Spirometry and CT Evidence of Emphysema in COPDGene, May 2018
Consultant360, Using and Interpreting Carbon Monoxide Diffusing Capacity (Dlco) Correctly, May 2016
ELSEVIER, The Importance of the Assessment of Pulmonary Function in COPD, July 2012
ATS/ERS, Interpretative strategies for lung function tests, April 2005
European Journal of Heart Failure, What can we learn from pulmonary function testing in heart failure?, Oct 2017